BioNTech SE (BNTX) stock
Close on Nov 12, 2026Market cap $21.36BP/E –Yield –
BioNTech SE grew revenue 4.3% to €2.87B over fiscal 2025. Free cash flow was €280.90M. At the latest close the market valued the company at €19.15B.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- €19.15B
- P/E ratio
- –
- Price to sales
- 6.67
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 1.47%
Fundamentals
- Revenue
- €2.87B
- Net income
- -€1.14B
- EPS, diluted
- -4.70 EUR
- Free cash flow
- €280.90M
Trading
- Previous close
- $87.65
- Open
- $86.70
- Day's range
- $84.80 – $86.97
- Volume
- 979,096
- Average volume (20 days)
- 1,039,570
- Beta (5 years)
- 0.82
- RSI (14 days)
- 38.8
- Volatility (1 year)
- 47.2%
- Relative volume
- 0.86×
- WACC
- 9.0%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | BNTX | S&P 500 | Difference | BNTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.3% | -2.7% | −8.6 pts | ||
| 3 months | -8.3% | -1.7% | −6.6 pts | ||
| Year to date | -10.7% | +11.9% | −22.6 pts | ||
| 1 year | -23.9% | +12.0% | −35.9 pts | ||
| 3 years | -14.6% | +78.2% | −92.8 pts | -5.1% | +21.2% |
| 5 years | -63.8% | +73.2% | −137.1 pts | -18.4% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BioNTech filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About BioNTech
Biological Products, (No Diagnostic Substances)
BioNTech is a biotechnology company focused on developing immunotherapies and specialized medical solutions. Its operations encompass cell and gene therapies, delivery technologies, peptide research, diagnostics, and artificial intelligence-driven discovery. The enterprise derives revenue from COVID-19 vaccines, licensing agreements, and external product sales. Its commercial relationships and key counterparties include major pharmaceutical collaborators, notably Pfizer and Bristol Myers Squibb, as well as institutional clients such as the German Federal Ministry of Health.
Company profile, executives and historyBioNTech stock: common questions
What is BioNTech's stock price?
BNTX closed at $85.04 on Nov 12, 2026, down 2.98% on the day.
What is BioNTech's market cap?
BioNTech was worth $21.36B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is BNTX's P/E ratio?
BioNTech lost money over fiscal 2025 (diluted EPS -4.70 EUR), so it has no meaningful P/E ratio.
How much revenue does BioNTech make?
BioNTech reported revenue of €2.87B for fiscal 2025, up 4.3% from a year earlier.
Does BioNTech pay a dividend?
No. BioNTech has not paid a cash dividend over the last twelve months.
How has BNTX stock performed over the past year?
Including dividends, BNTX returned -23.9% over the past year, against +12.0% for the S&P 500.
Who are BioNTech's competitors?
Companies most similar to BioNTech by business, industry and size include MRNA, QGEN, EXEL, HALO, ALVO.
See a number that looks wrong?